Onconetix, Inc. (ONCO)
0.73
+0.06
(+8.26%)
USD |
NASDAQ |
Sep 03, 16:00
0.73
0.00 (0.00%)
After-Hours: 20:00
Onconetix Research and Development Expense (Annual) : -0.0661M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | -0.0661M |
| December 31, 2024 | 0.1544M |
| December 31, 2023 | 1.949M |
| December 31, 2022 | 4.130M |
| Date | Value |
|---|---|
| December 31, 2021 | 1.325M |
| December 31, 2020 | 0.5249M |
| December 31, 2019 | 0.0602M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Aprea Therapeutics, Inc. | 7.043M |
| ACADIA Pharmaceuticals, Inc. | 328.80M |
| Alnylam Pharmaceuticals, Inc. | 1.320B |
| Anika Therapeutics, Inc. | 25.77M |
| Savara, Inc. | 81.40M |